Kevin F. Staveley-O’cArroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin F. Staveley-O’cArroll has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Niraj Jaysukh Gusani
Baptist MD Anderson Canc Ctr, Sect Surg Oncol, Jacksonville, FL 32207 USA
4 shared publications Serene Shereef
Department of Surgery, Division of Surgical Oncology, Pennsylvania State University College of Medicine, Hershey, PA
4 shared publicationsDiego M. Avella
Department of Surgery, Division of Surgical Oncology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
3 shared publicationsEric T. Kimchi
Department of Surgery, Division of Surgical Oncology, Pennsylvania State University College of Medicine, Hershey, PA
3 shared publicationsMandeep Sehmbey
Penn State College of Medicine
3 shared publications- Mehrdad Nikfarjam
Department of Surgery, University of Melbourne, Heidelberg, Australia
3 shared publications
Latest Publications
- 21 November 2012
- Published by Springer Nature
- Vol. 779, 67-90
Impact of Genetic Targets on Cancer Therapy: Hepatocellular Cancer
Understanding cancer at the genetic level had gained significant attention over the last decade since the human genome was first sequenced in 2001. For hepatocellular carcinoma (HCC) a number of genome-wide profiling studies have been published. These studies have provided us with gene sets, based on which we can now classify tumors and have an idea about the likely clinical outcomes. In addition to that, genomic profiling for HCC has provided us a better understanding of the carcinogenesis process and identifies key steps at multiple levels (i.e. Genetics, molecular pathways) that can be potential targets for treatment and prevention. Although still an incurable disease, unresectable HCC has one proven systemic therapy, sorafenib, and many under active investigation. With advancement in technology and understanding of hepatocarcinogenesis, scientists hope to provide true personalized treatment for this disease in the near future. In this review article we discuss advances in understanding genetics and pathogenesis of HCC and the currently available and ongoing trials for targeted therapies. These emerging therapies may guide the development of more effective treatments or possibly a cure for HCC.
- 21 November 2012
- Published by Springer Nature
- Vol. 779, 67-90
Impact of Genetic Targets on Cancer Therapy: Hepatocellular Cancer
Understanding cancer at the genetic level had gained significant attention over the last decade since the human genome was first sequenced in 2001. For hepatocellular carcinoma (HCC) a number of genome-wide profiling studies have been published. These studies have provided us with gene sets, based on which we can now classify tumors and have an idea about the likely clinical outcomes. In addition to that, genomic profiling for HCC has provided us a better understanding of the carcinogenesis process and identifies key steps at multiple levels (i.e. Genetics, molecular pathways) that can be potential targets for treatment and prevention. Although still an incurable disease, unresectable HCC has one proven systemic therapy, sorafenib, and many under active investigation. With advancement in technology and understanding of hepatocarcinogenesis, scientists hope to provide true personalized treatment for this disease in the near future. In this review article we discuss advances in understanding genetics and pathogenesis of HCC and the currently available and ongoing trials for targeted therapies. These emerging therapies may guide the development of more effective treatments or possibly a cure for HCC.
- Open Access
- 2 September 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 55 (1) , 141-152
Regression of Established Hepatocellular Carcinoma Is Induced by Chemoimmunotherapy in An Orthotopic Murine Model
The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches. In this study we evaluated the efficacy of a novel chemoimmunotherapeutic strategy to control HCC and investigated the underlying mechanism that increased the antitumor immune response. We developed a novel orthotopic mouse model of HCC through seeding of tumorigenic hepatocytes from SV40 T antigen (Tag) transgenic MTD2 mice into the livers of syngeneic C57BL/6 mice. These MTD2–derived hepatocytes form Tag–expressing HCC tumors specifically within the liver. This approach provides a platform to test therapeutic strategies and antigen–specific immune–directed therapy in an immunocompetent murine model. Using this model we tested the efficacy of a combination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor, and adoptive transfer of tumor antigen–specific CD8+ T cells to eliminate HCC. Sunitinib treatment alone promoted a transient reduction in tumor size. Sunitinib treatment combined with adoptive transfer of tumor antigen–specific CD8+ T cells led to elimination of established tumors without recurrence. In vitro studies revealed that HCC growth was inhibited through suppression of STAT3 signaling. In addition, sunitinib treatment of tumor–bearing mice was associated with suppression of STAT3 and a block in T–cell tolerance. Conclusion : These findings indicate that sunitinib inhibits HCC tumor growth directly through the STAT3 pathway and prevents tumor antigen–specific CD8+ T–cell tolerance, thus defining a synergistic chemoimmunotherapeutic approach for HCC. (Hepatology 2012;55:141–152)
- 2 September 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 55 (1) , 141-152
Open AccessRegression of Established Hepatocellular Carcinoma Is Induced by Chemoimmunotherapy in An Orthotopic Murine Model
The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches. In this study we evaluated the efficacy of a novel chemoimmunotherapeutic strategy to control HCC and investigated the underlying mechanism that increased the antitumor immune response. We developed a novel orthotopic mouse model of HCC through seeding of tumorigenic hepatocytes from SV40 T antigen (Tag) transgenic MTD2 mice into the livers of syngeneic C57BL/6 mice. These MTD2–derived hepatocytes form Tag–expressing HCC tumors specifically within the liver. This approach provides a platform to test therapeutic strategies and antigen–specific immune–directed therapy in an immunocompetent murine model. Using this model we tested the efficacy of a combination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor, and adoptive transfer of tumor antigen–specific CD8+ T cells to eliminate HCC. Sunitinib treatment alone promoted a transient reduction in tumor size. Sunitinib treatment combined with adoptive transfer of tumor antigen–specific CD8+ T cells led to elimination of established tumors without recurrence. In vitro studies revealed that HCC growth was inhibited through suppression of STAT3 signaling. In addition, sunitinib treatment of tumor–bearing mice was associated with suppression of STAT3 and a block in T–cell tolerance. Conclusion : These findings indicate that sunitinib inhibits HCC tumor growth directly through the STAT3 pathway and prevents tumor antigen–specific CD8+ T–cell tolerance, thus defining a synergistic chemoimmunotherapeutic approach for HCC. (Hepatology 2012;55:141–152)
- 1 May 2009
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (5) , 915-921
Additional Organ Resection Combined with Pancreaticoduodenectomy does not Increase Postoperative Morbidity and Mortality
- 1 May 2009
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (5) , 915-921
Additional Organ Resection Combined with Pancreaticoduodenectomy does not Increase Postoperative Morbidity and Mortality
- 27 November 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (7) , 1860-1867
Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy
The outcome of patients with colorectal liver metastases (CLM) undergoing surgical resection in the era of effective chemotherapy is not widely reported. In addition, factors associated with...
- 27 November 2008
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (7) , 1860-1867
Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy
The outcome of patients with colorectal liver metastases (CLM) undergoing surgical resection in the era of effective chemotherapy is not widely reported. In addition, factors associated with...
- 11 June 2008
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 12 (11) , 2023-2031
Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy
- 11 June 2008
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 12 (11) , 2023-2031
Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy